Technical Analysis for RARX - Ra Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 23.88 -4.48% -1.12
RARX closed down 4.48 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical RARX trend table...

Date Alert Name Type % Chg
Mar 22 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Outside Day Range Expansion 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 21 Hammer Candlestick Bullish -4.48%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -4.48%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.48%
Mar 21 Doji - Bullish? Reversal -4.48%

Older signals for RARX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Its peptide chemistry platform delivers enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. The company's lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It also develops Factor D inhibition for age-related macular degeneration and geographic atrophy; Oral C5 inhibitor for refractory generalized myasthenia gravis, lupus nephritis, and central nervous system (CNS) diseases; C1s inhibition for autoimmune/CNS diseases. The company has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Medicine Biopharmaceutical Medical Specialties Diseases Immunology Antibodies Autoimmune Diseases Rare Diseases Autoimmunity Age Related Macular Degeneration Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Myasthenia Gravis Lupus Nephritis Pnh Therapeutics For The Treatment Of Diseases
Is RARX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.68
52 Week Low 4.78
Average Volume 420,159
200-Day Moving Average 15.4709
50-Day Moving Average 21.2904
20-Day Moving Average 23.245
10-Day Moving Average 25.984
Average True Range 1.6088
ADX 30.73
+DI 23.4935
-DI 18.7039
Chandelier Exit (Long, 3 ATRs ) 22.8536
Chandelier Exit (Short, 3 ATRs ) 22.8864
Upper Bollinger Band 29.5864
Lower Bollinger Band 16.9036
Percent B (%b) 0.55
BandWidth 54.561411
MACD Line 1.4884
MACD Signal Line 1.5052
MACD Histogram -0.0168
Fundamentals Value
Market Cap 539.89 Million
Num Shares 22.6 Million
EPS -2.84
Price-to-Earnings (P/E) Ratio -8.41
Price-to-Sales 0.00
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.55
Resistance 3 (R3) 26.69 25.93 26.11
Resistance 2 (R2) 25.93 25.25 25.87 25.96
Resistance 1 (R1) 24.91 24.83 24.53 24.77 25.81
Pivot Point 24.15 24.15 23.97 24.09 24.15
Support 1 (S1) 23.13 23.47 22.75 22.99 21.95
Support 2 (S2) 22.37 23.05 22.31 21.80
Support 3 (S3) 21.35 22.37 21.66
Support 4 (S4) 21.21